作者:PullaReddy Boggu、Eeda Venkateswararao、Manoj Manickam、Dajin Kwak、Youngsoo Kim、Sang-Hun Jung
DOI:10.1016/j.bmc.2016.03.012
日期:2016.4
previously reported. Although most of the benzimidazole derivatives showed strong inhibitory activity in low micromolar potency, 2-(4-methoxybenzyl)-1H-benzo[d]imidazole (3m; IC50 = 1.7 μM) and 2-(2-methoxybenzyl)-1H-benzo[d]imidazole (3n; IC50 = 2.4 μM) showed the best inhibition. The structure activity relationship revealed that 2-benzylbenzimidazole scaffold with hydrogen bonding acceptor on phenyl
为了找到新的核因子κB活性抑制剂,合理设计,合成和系统研究了一系列苯并咪唑衍生物对RAW 264.7细胞中LPS诱导的NF-κB抑制的体外活性,基于基于柔性查尔酮JSH的SEAP分析(先前报道的((E)-1-(2-羟基-6-(异戊氧基)苯基)-3-(4-羟基苯基)丙-2-烯-1-酮)。尽管大多数苯并咪唑衍生物在低微摩尔浓度下均显示出强大的抑制活性,但是2-(4-甲氧基苄基)-1 H-苯并[ d ]咪唑(3m; IC 50 = 1.7μM)和2-(2-甲氧基苄基)-1 H-苯并[ d ]咪唑(3n ; IC50 = 2.4μM)表现出最好的抑制作用。结构活性关系表明,在苯环上带有氢键受体的2-苄基苯并咪唑支架以药效团的形式出现。